Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) Trial
NCT03391973Phase 2Completed
- Sponsor
- American Health Staffing Group
- Start
- Aug 2018
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in carcinoma of unknown primary (CUP), sponsored by American Health Staffing Group. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT03391973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391973.